法维拉韦（25毫克）-Favipiravir (25 mg)-生化试剂-艾美捷科技有限公司

PRODUCT CENTER

生化试剂

产品中心

当前位置：首页 > 产品中心 > 分子生化产品 > 生化试剂

购买方式: Biosensis中国区现货中心已经建立，大部分产品中国有现货库存。银行转账、电汇、支票、现金，在线支付宝及网银支付，或直接与我们电话联系400-6800-868

背景资料: 该产品别称为6-Fluoro-3-hydroxypyrazine-2-carboxamide; CAS 259793-96-9; T-705，应用类型为：Neutralize，Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 _g/ml for the influenza A viruses, from 0.039 to 0.089 _g/ml for the influenza B viruses, and from 0.030 to 0.057 _g/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 _g/ml. [1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. [

产品描述: Fingolimod (FTY720) is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod (trade name Gilenya, Novartis) is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system. Fingolimod was approved as a first-in-class, orally active drug for relapsing multiple sclerosis in 2010, and its applications in other disease conditions are currently under clinical trials.

保存建议: Store desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 1 month. Prevent multiple freeze-thaw cycles.

其他: Biosensis专注于神经科学领域的抗体和试剂的开发，特别是神经营养因子和神经营养因子受体。近30年来，Biosensis一直是该领域的全球领航者和OEM供应商。除神经营养因子，我们的神经科学产品组合还被广泛用于神经退行性疾病、神经发育和神经代谢的研究。重点研究领域包括阿尔茨海默氏症（AD）、帕金森氏症（PD）和肌萎缩侧索硬化（ALS）疾病，以及自噬和代谢应激障碍，包括肥胖、代谢综合征的研究、神经免疫学和炎症。Biosensis的产品系列不仅包括持续增长的神经科学研究抗体系列，还包括200多种定量研究ELISAs试剂盒（1板或2板，自由选择），组织染色（退化神经元染色试剂盒、病理髓鞘染色试剂盒、淀粉样斑块染色试剂等）和细胞可视化试剂（染色）以及针对神经科学和细胞疾病研究的纯化的蛋白质。我们的抗体和试剂已被广泛应用于各种技术，包括蛋白质印迹，免疫组织化学，流式分析，共聚焦显微镜实时成像，生物抑制和细胞培养以及克隆。